Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'"
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2024-12 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | Molecular psychiatry |
container_volume | |
creator | Levinstein, Marjorie R De Oliveira, Paulo A Casajuana-Martin, Nil Quiroz, Cesar Budinich, Reece C Rais, Rana Rea, William Ventriglia, Emilya N Llopart, Natàlia Casadó-Anguera, Verònica Moreno, Estefanía Walther, Donna Glatfelter, Grant C Weinshenker, David Zarate, Jr, Carlos A Casadó, Vicent Baumann, Michael H Pardo, Leonardo Ferré, Sergi Michaelides, Michael |
description | |
doi_str_mv | 10.1038/s41380-024-02864-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146531792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146531792</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-629bc3fdfaa9b1fb4fc448b573c81b069a60d8cc0cca84e4943efb78d0a1fbd43</originalsourceid><addsrcrecordid>eNpNkM1KAzEUhYMotlZfwIWEbloXo0mTmckspdQfKAhq1yU_d9rIzGRMUqTv4eP4DD6TU63g4nIPh3M_OBehc0quKGHiOnDKBEnIhHcjMp6wA9SnPM-SNM3F4T_dQychvBKyM9Jj1GNFxgqaZ3308QRttcXR4eEcYgS_k3ENeGZsdB57WElvbLPCo0Vj3zaA27X0tdTObBtZW41b71rw0ULAsjG4cu9Yqk0AXFmpbGXjFrvyB_n1mbjWOms6qoZ2h6_sanc0fr5MaohraVwDo-EpOiplFeBsvwdocTt7md4n88e7h-nNPGkppzHJJoXSrDSllIWipeKl5lyoNGdaUEWyQmbECK2J1lJw4AVnUKpcGCK7tOFsgMa_3K5DVy3EZW2DhqqSDbhNWDLKs5TRvJh00Yt9dKNqMMvW21r67fLvk-wbylp5dg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146531792</pqid></control><display><type>article</type><title>Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'"</title><source>SpringerLink Journals - AutoHoldings</source><creator>Levinstein, Marjorie R ; De Oliveira, Paulo A ; Casajuana-Martin, Nil ; Quiroz, Cesar ; Budinich, Reece C ; Rais, Rana ; Rea, William ; Ventriglia, Emilya N ; Llopart, Natàlia ; Casadó-Anguera, Verònica ; Moreno, Estefanía ; Walther, Donna ; Glatfelter, Grant C ; Weinshenker, David ; Zarate, Jr, Carlos A ; Casadó, Vicent ; Baumann, Michael H ; Pardo, Leonardo ; Ferré, Sergi ; Michaelides, Michael</creator><creatorcontrib>Levinstein, Marjorie R ; De Oliveira, Paulo A ; Casajuana-Martin, Nil ; Quiroz, Cesar ; Budinich, Reece C ; Rais, Rana ; Rea, William ; Ventriglia, Emilya N ; Llopart, Natàlia ; Casadó-Anguera, Verònica ; Moreno, Estefanía ; Walther, Donna ; Glatfelter, Grant C ; Weinshenker, David ; Zarate, Jr, Carlos A ; Casadó, Vicent ; Baumann, Michael H ; Pardo, Leonardo ; Ferré, Sergi ; Michaelides, Michael</creatorcontrib><identifier>ISSN: 1476-5578</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-024-02864-3</identifier><identifier>PMID: 39639176</identifier><language>eng</language><publisher>England</publisher><ispartof>Molecular psychiatry, 2024-12</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1764-3825 ; 0000-0002-3678-6215 ; 0000-0002-1747-1779 ; 0000-0002-2491-5753 ; 0000-0003-4360-1503 ; 0000-0002-9007-274X ; 0000-0002-3127-2901 ; 0000-0003-0398-4917</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39639176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levinstein, Marjorie R</creatorcontrib><creatorcontrib>De Oliveira, Paulo A</creatorcontrib><creatorcontrib>Casajuana-Martin, Nil</creatorcontrib><creatorcontrib>Quiroz, Cesar</creatorcontrib><creatorcontrib>Budinich, Reece C</creatorcontrib><creatorcontrib>Rais, Rana</creatorcontrib><creatorcontrib>Rea, William</creatorcontrib><creatorcontrib>Ventriglia, Emilya N</creatorcontrib><creatorcontrib>Llopart, Natàlia</creatorcontrib><creatorcontrib>Casadó-Anguera, Verònica</creatorcontrib><creatorcontrib>Moreno, Estefanía</creatorcontrib><creatorcontrib>Walther, Donna</creatorcontrib><creatorcontrib>Glatfelter, Grant C</creatorcontrib><creatorcontrib>Weinshenker, David</creatorcontrib><creatorcontrib>Zarate, Jr, Carlos A</creatorcontrib><creatorcontrib>Casadó, Vicent</creatorcontrib><creatorcontrib>Baumann, Michael H</creatorcontrib><creatorcontrib>Pardo, Leonardo</creatorcontrib><creatorcontrib>Ferré, Sergi</creatorcontrib><creatorcontrib>Michaelides, Michael</creatorcontrib><title>Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'"</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><issn>1476-5578</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkM1KAzEUhYMotlZfwIWEbloXo0mTmckspdQfKAhq1yU_d9rIzGRMUqTv4eP4DD6TU63g4nIPh3M_OBehc0quKGHiOnDKBEnIhHcjMp6wA9SnPM-SNM3F4T_dQychvBKyM9Jj1GNFxgqaZ3308QRttcXR4eEcYgS_k3ENeGZsdB57WElvbLPCo0Vj3zaA27X0tdTObBtZW41b71rw0ULAsjG4cu9Yqk0AXFmpbGXjFrvyB_n1mbjWOms6qoZ2h6_sanc0fr5MaohraVwDo-EpOiplFeBsvwdocTt7md4n88e7h-nNPGkppzHJJoXSrDSllIWipeKl5lyoNGdaUEWyQmbECK2J1lJw4AVnUKpcGCK7tOFsgMa_3K5DVy3EZW2DhqqSDbhNWDLKs5TRvJh00Yt9dKNqMMvW21r67fLvk-wbylp5dg</recordid><startdate>20241206</startdate><enddate>20241206</enddate><creator>Levinstein, Marjorie R</creator><creator>De Oliveira, Paulo A</creator><creator>Casajuana-Martin, Nil</creator><creator>Quiroz, Cesar</creator><creator>Budinich, Reece C</creator><creator>Rais, Rana</creator><creator>Rea, William</creator><creator>Ventriglia, Emilya N</creator><creator>Llopart, Natàlia</creator><creator>Casadó-Anguera, Verònica</creator><creator>Moreno, Estefanía</creator><creator>Walther, Donna</creator><creator>Glatfelter, Grant C</creator><creator>Weinshenker, David</creator><creator>Zarate, Jr, Carlos A</creator><creator>Casadó, Vicent</creator><creator>Baumann, Michael H</creator><creator>Pardo, Leonardo</creator><creator>Ferré, Sergi</creator><creator>Michaelides, Michael</creator><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1764-3825</orcidid><orcidid>https://orcid.org/0000-0002-3678-6215</orcidid><orcidid>https://orcid.org/0000-0002-1747-1779</orcidid><orcidid>https://orcid.org/0000-0002-2491-5753</orcidid><orcidid>https://orcid.org/0000-0003-4360-1503</orcidid><orcidid>https://orcid.org/0000-0002-9007-274X</orcidid><orcidid>https://orcid.org/0000-0002-3127-2901</orcidid><orcidid>https://orcid.org/0000-0003-0398-4917</orcidid></search><sort><creationdate>20241206</creationdate><title>Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'"</title><author>Levinstein, Marjorie R ; De Oliveira, Paulo A ; Casajuana-Martin, Nil ; Quiroz, Cesar ; Budinich, Reece C ; Rais, Rana ; Rea, William ; Ventriglia, Emilya N ; Llopart, Natàlia ; Casadó-Anguera, Verònica ; Moreno, Estefanía ; Walther, Donna ; Glatfelter, Grant C ; Weinshenker, David ; Zarate, Jr, Carlos A ; Casadó, Vicent ; Baumann, Michael H ; Pardo, Leonardo ; Ferré, Sergi ; Michaelides, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-629bc3fdfaa9b1fb4fc448b573c81b069a60d8cc0cca84e4943efb78d0a1fbd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levinstein, Marjorie R</creatorcontrib><creatorcontrib>De Oliveira, Paulo A</creatorcontrib><creatorcontrib>Casajuana-Martin, Nil</creatorcontrib><creatorcontrib>Quiroz, Cesar</creatorcontrib><creatorcontrib>Budinich, Reece C</creatorcontrib><creatorcontrib>Rais, Rana</creatorcontrib><creatorcontrib>Rea, William</creatorcontrib><creatorcontrib>Ventriglia, Emilya N</creatorcontrib><creatorcontrib>Llopart, Natàlia</creatorcontrib><creatorcontrib>Casadó-Anguera, Verònica</creatorcontrib><creatorcontrib>Moreno, Estefanía</creatorcontrib><creatorcontrib>Walther, Donna</creatorcontrib><creatorcontrib>Glatfelter, Grant C</creatorcontrib><creatorcontrib>Weinshenker, David</creatorcontrib><creatorcontrib>Zarate, Jr, Carlos A</creatorcontrib><creatorcontrib>Casadó, Vicent</creatorcontrib><creatorcontrib>Baumann, Michael H</creatorcontrib><creatorcontrib>Pardo, Leonardo</creatorcontrib><creatorcontrib>Ferré, Sergi</creatorcontrib><creatorcontrib>Michaelides, Michael</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levinstein, Marjorie R</au><au>De Oliveira, Paulo A</au><au>Casajuana-Martin, Nil</au><au>Quiroz, Cesar</au><au>Budinich, Reece C</au><au>Rais, Rana</au><au>Rea, William</au><au>Ventriglia, Emilya N</au><au>Llopart, Natàlia</au><au>Casadó-Anguera, Verònica</au><au>Moreno, Estefanía</au><au>Walther, Donna</au><au>Glatfelter, Grant C</au><au>Weinshenker, David</au><au>Zarate, Jr, Carlos A</au><au>Casadó, Vicent</au><au>Baumann, Michael H</au><au>Pardo, Leonardo</au><au>Ferré, Sergi</au><au>Michaelides, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'"</atitle><jtitle>Molecular psychiatry</jtitle><addtitle>Mol Psychiatry</addtitle><date>2024-12-06</date><risdate>2024</risdate><issn>1476-5578</issn><eissn>1476-5578</eissn><cop>England</cop><pmid>39639176</pmid><doi>10.1038/s41380-024-02864-3</doi><orcidid>https://orcid.org/0000-0002-1764-3825</orcidid><orcidid>https://orcid.org/0000-0002-3678-6215</orcidid><orcidid>https://orcid.org/0000-0002-1747-1779</orcidid><orcidid>https://orcid.org/0000-0002-2491-5753</orcidid><orcidid>https://orcid.org/0000-0003-4360-1503</orcidid><orcidid>https://orcid.org/0000-0002-9007-274X</orcidid><orcidid>https://orcid.org/0000-0002-3127-2901</orcidid><orcidid>https://orcid.org/0000-0003-0398-4917</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1476-5578 |
ispartof | Molecular psychiatry, 2024-12 |
issn | 1476-5578 1476-5578 |
language | eng |
recordid | cdi_proquest_miscellaneous_3146531792 |
source | SpringerLink Journals - AutoHoldings |
title | Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'" |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A33%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reply%20to%20%22Letter%20to%20the%20Editor%20regarding%20'Unique%20pharmacodynamic%20properties%20and%20low%20abuse%20liability%20of%20the%20%CE%BC-opioid%20receptor%20ligand%20(S)-methadone'%22&rft.jtitle=Molecular%20psychiatry&rft.au=Levinstein,%20Marjorie%20R&rft.date=2024-12-06&rft.issn=1476-5578&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-024-02864-3&rft_dat=%3Cproquest_pubme%3E3146531792%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146531792&rft_id=info:pmid/39639176&rfr_iscdi=true |